Zemplar
Company: Abbott Laboratories
Approval Status: Approved April 1998
Treatment for: secondary hyperparathyroidism associated with chronic renal failure
Areas: Endocrinology; Nephrology/Urology
| General Information | Clinical Results | Side Effects |
General Information
Zemplar (paricalcitol injection) has been approved for the treatment of secondary hyperparathyroidism associated with chronic renal failure. Zemplar is the first vitamin D analog available to treat secondary hyperparathyroidism.
Clinical Results
In three placebo-controlled studies, chronic renal failure patients treated with Zemplar achieved a mean parathyroid hormone (PTH) reduction of 30% in six weeks. Additionally there was no difference in incidence of hypercalcemia or hyperphosphatemia when compared to placebo.
Side Effects
In four, placebo-controlled, double blind, multi center studies, there was no significant difference in the incidence rate for adverse events between Zemplar and placebo-treated patients. The three most frequently reported events in the Zemplar clinical studies were nausea, vomiting and edema, which are commonly seen in hemodialysis patients.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
